Golexanolone improves fatigue, motor incoordination and gait and memory in rats with bile duct ligation.

Fecha de publicación: Fecha Ahead of Print:

Autores de CIPF

Participantes ajenos a CIPF

  • Martinez-García M
  • Giménez-Garzó C
  • Mincheva G
  • Doverskog M
  • Jones DEJ
  • Balzano T

Grupos de Investigación

Abstract

Many patients with the chronic cholestatic liver disease primary biliary cholangitis (PBC) show fatigue and cognitive impairment that reduces their quality of life. Likewise, rats with bile duct ligation (BDL) are a model of cholestatic liver disease. Current PBC treatments do not improve symptomatic alterations such as fatigue or cognitive impairment and new, more effective treatments are therefore required. Golexanolone reduces the potentiation of GABA A receptors activation by neurosteroids. Golexanolone reduces peripheral inflammation and neuroinflammation and improves cognitive and motor function in rats with chronic hyperammonemia. The aims of the present study were to assess if golexanolone treatment improves fatigue and cognitive and motor function in cholestatic BDL rats and if this is associated with improvement of peripheral inflammation, neuroinflammation, and GABAergic neurotransmission in the cerebellum.

Datos de la publicación

ISSN/ISSNe:
1478-3223, 1478-3231

LIVER INTERNATIONAL  WILEY-BLACKWELL

Tipo:
Article
Páginas:
433-445
PubMed:
38010893

Citas Recibidas en Web of Science: 13

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • cholestatic liver disease, fatigue, golexanolone, locomotor gait, memory, primary biliary cholangitis

Campos de Estudio

Compartir